Impact of Platelet Hyperreactivity and Diabetes Mellitus on Ischemic Stroke Recurrence: A Single-Center Cohort Clinical Study
Open Access
- 1 March 2024
- journal article
- research article
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 1127-1138
Abstract
Purpose: Ischemic stroke recurrence (ISR) is prevented by inhibiting platelet function. To investigate the impact of high on-treatment platelet reactivity (HTPR) assessed by thromboelastography (TEG) and its risk factors on ISR in individuals who have experienced acute ischemic stroke (AIS) receiving dual anti-platelet therapy (DAPT). Patients and Methods: At the end of follow-up, a total of 264 patients who met the criteria were enrolled in this cohort study. The primary endpoint event was a recurrence of ischemic stroke within 90 days of onset. Results: The ISR rate was 7.2% (19/264). The recurrence rate in the HTPR group was 15.1% (8/53), which was significantly higher than the 5.2% (11/211) in the non-HTPR group (p = 0.013), and the type 2 diabetes mellitus (T2DM) group (12.5%, 10/80) was also significantly higher compared to the non-T2DM group (4.9%, 9/184) (p = 0.028). T2DM was an isolated risk factor for HTPR (adjusted OR = 3.06, 95% CI 1.57– 5.98, P = 0.001). Kaplan-Meier plots showed that the cumulative risk (CR) of ISR was statistically different in the HTPR and T2DM groups compared to the non-HTPR group (log-rank P = 0.009) and the non-T2DM group (log-rank P = 0.026), respectively. The HTPR and T2DM groups had greater hazard ratios (HR) of ISR than the non-HTPR (adjusted HR = 2.78, 95% CI 1.06– 7.32, P = 0.038) and non-T2DM (adjusted HR = 2.64, 95% CI 1.01– 6.92, P = 0.049) groups. Conclusion: Both HTPR and T2DM are linked to ISR. Platelet Inhibition Rate (PIR) of TEG can early identify patients who are at high risk for having another ischemic stroke in patients undergoing DAPT, and this study may offer more evidence in favor of clinically personalized treatment and secondary prevention tactics.Keywords
This publication has 38 references indexed in Scilit:
- Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysisJournal of Neurology, 2020
- Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to ClopidogrelJACC: Cardiovascular Interventions, 2020
- PXR polymorphisms have impact on the clinical efficacy of clopidogrel in patients undergoing percutaneous coronary interventionGene, 2018
- Aspirin and clopidogrel high on‐treatment platelet reactivity and genetic predictors in peripheral arterial diseaseCatheterization and Cardiovascular Interventions, 2018
- Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese PopulationJournal of Stroke and Cerebrovascular Diseases, 2016
- A Comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 Assay for the Assessment of Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary InterventionJournal of Clinical Laboratory Analysis, 2012
- Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetesDiabetes Research and Clinical Practice, 2011
- Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery DiseaseJACC, 2011
- Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary InterventionJACC, 2007
- Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet TreatmentJACC, 2006